Blood Type Not Associated With COVID-19 Outcomes
No associations seen for disease susceptibility, severity, or outcomes for either White populations or diverse populations
COVID19
NIH: Anti-SARS-CoV-2 Monoclonal Antibody Therapy Guidance Updated
Given concerns over decreased susceptibility of SARS-CoV-2 variants, the panel recommends against the use of bamlanivimab monotherapy.
COVID-19 Cases Climb in the Midwest as British Variant Takes Hold in US
Officials warn of fourth wave of COVID-19 cases this spring due to emergence of more contagious variants. easing of social distancing
Considerable Neurologic, Psychiatric Morbidity Reported After COVID-19
Estimated incidence of neurological or psychiatric diagnosis was 33.62 percent among 236,379 patients
Oral COVID-19 Vaccine Being Tested
T cell oral vaccine targets the globe in the middle of the virus, a part less prone to mutation
MPR Weekly Dose Podcast 74
Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased for Moderna; A new ADHD drug is approved; And the FDA has issued a safety communication regarding lamotrigine.
Moderna COVID-19 Vaccine: Antibody Persistence Observed Through 6 Months After Second Dose
The study analyzed 33 healthy adult participants in the National Institutes of Health (NIH)-led phase 1 study of the Moderna COVID-19 vaccine at 6 months following the second dose.
Mixed Results for Baricitinib in Trial of Hospitalized COVID-19 Patients
Findings showed that the trial did not meet statistical significance on the primary endpoint.
COVID-19 Vaccination During Pregnancy May Protect Infant
The observed IgG transfer ratio demonstrates an infant antibody level about equal to maternal level
Two Peaks in MIS-C Followed COVID-19 Peaks in the US
Lowest proportion of severe manifestations seen in patients aged 0 to 4 years, but 44.3 percent admitted for intensive care
